Pharmaceutical News

RSS
BMA comment on Shipman Inquiry's recommended changes to the regulation of controlled drugs in the community

BMA comment on Shipman Inquiry's recommended changes to the regulation of controlled drugs in the community

New early breast cancer treatment significantly reduces the risk of cancer returning

New early breast cancer treatment significantly reduces the risk of cancer returning

Quality HIV/AIDS treatment eased through extended agreement about lowest-priced drugs and diagnostics

Quality HIV/AIDS treatment eased through extended agreement about lowest-priced drugs and diagnostics

Strategic analysis of the breast cancer therapeutics pipeline

Strategic analysis of the breast cancer therapeutics pipeline

Thalidomide's role in fighting blood disorders, such as multiple myeloma

Thalidomide's role in fighting blood disorders, such as multiple myeloma

Fluoxetine, orlistat, and sibutramine can diabetics achieve significant weight loss

Fluoxetine, orlistat, and sibutramine can diabetics achieve significant weight loss

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Nevirapine effective in reducing the risk of transmission of HIV at birth

Nevirapine effective in reducing the risk of transmission of HIV at birth

ATS receives a US $3.8 million order for a manufacturing system for new drug delivery technology

ATS receives a US $3.8 million order for a manufacturing system for new drug delivery technology

Health Canada warning on Trazodone interaction with certain medications

Health Canada warning on Trazodone interaction with certain medications

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

Natural products to be developed as anti-cancer therapeutics

Natural products to be developed as anti-cancer therapeutics

Chiron has received a license for its new meningococcal B vaccine for New Zealand

Chiron has received a license for its new meningococcal B vaccine for New Zealand

Endo announces agreement With FDA for new trial design of oxymorphone extended-release tablets

Endo announces agreement With FDA for new trial design of oxymorphone extended-release tablets

Pfizer focuses on enabling America's 43 million uninsured to obtain medicines at significant savings

Pfizer focuses on enabling America's 43 million uninsured to obtain medicines at significant savings

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Report highlights progress on cancer drugs but more can be done

Report highlights progress on cancer drugs but more can be done

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.